Biogen

YTD

ALL

Trade Biogen 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About BIIB

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis.

CEO

Christopher A. Viehbacher

CEOChristopher A. Viehbacher

Employees

7,605

Employees7,605

Headquarters

Cambridge, Massachusetts

HeadquartersCambridge, Massachusetts

Founded

1978

Founded1978

Employees

7,605

Employees7,605

BIIB Key Statistics

Market cap

20.74B

Market cap20.74B

Price-Earnings ratio

12.57

Price-Earnings ratio12.57

Dividend yield

—

Dividend yield—

Average volume

1.88M

Average volume1.88M

High today

$144.17

High today$144.17

Low today

$139.35

Low today$139.35

Open price

$141.33

Open price$141.33

Volume

626.36K

Volume626.36K

52 Week high

$238.00

52 Week high$238.00

52 Week low

$128.51

52 Week low$128.51

BIIB News

Simply Wall St 5d

We Think Biogen's Healthy Earnings Might Be Conservative

Biogen Inc.'s ( ) recent earnings report didn't offer any surprises, with the shares unchanged over the last week. We did some digging, and we think that invest...

TipRanks 6d

Strategic Collaboration Between Stoke Therapeutics and Biogen Fuels Buy Rating for Zorevunersen Development

TD Cowen analyst Yaron Werber has maintained their bullish stance on STOK stock, giving a Buy rating today. Discover the Best Stocks and Maximize Your Portfoli...

Benzinga 6d

Biogen Strengthens Pipeline With Stoke Therapeutic's Dravet Syndrome Candidate Via Multi-Million Dollar Deal

On Tuesday, Biogen Inc. BIIB and Stoke Therapeutics, Inc. STOK collaborated to develop and commercialize zorevunersen for Dravet syndrome in all territories out...

Analyst ratings

51%

of 37 ratings

Buy

48.6%

Hold

51.4%

Sell

More BIIB News

TipRanks 6d

Strategic Collaboration with Biogen Boosts Stoke Therapeutics’ Financial and Market Position

Analyst Joseph Stringer of Needham maintained a Buy rating on Stoke Therapeutics (STOK – Research Report), retaining the price target of $22.00. Discover the B...

Seeking Alpha 6d

Biogen and Stoke Therapeutics collaborates to develop Dravet syndrome treatment globally

Biogen (NASDAQ:BIIB) and Stoke Therapeutics (NASDAQ:STOK) said on Tuesday they are collaborating to develop and commercialize zorevunersen, an investigational t...